Antibodies, Bispecific – Page 5

Merus’ Bispecific Antibody Therapy Shows Promising Early Results in Cancer Treatment

1 year ago talkbio0Tagged Antibodies, Bispecific, ASCO, Cancer Therapeutic Procedure, Expectations, investor, Merus

Merus, bispecific antibody, cancer treatment, early results, investor expectations, ASCO

MacroGenics Reviews Safety Protocols Following Three Patient Deaths in Prostate Cancer Drug Trial

1 year ago talkbio0Tagged Antibodies, Bispecific, Cessation of life, MacroGenics, Malignant neoplasm of prostate, margetuximab, Phase 2 trial, safety review

MacroGenics, Phase 2 trial, prostate cancer, patient deaths, safety review, margetuximab, bispecific antibody

Brukinsa by BeiGene Secures FDA Approval for Follicular Lymphoma Amid Imbruvica Setbacks

2 years ago talkbio0Tagged Accelerated, Antibodies, Bispecific, Approved, BeiGene, Brukinsa, Chimeric Antigen Receptor T-cells, Clinical Trials, Combined Modality Therapy, competition, Disease Progression, Gazyva, Lymphoma, Follicular, obinutuzumab, ORR, Overall response rate, Rosewood, Toxicity aspects, United States Food and Drug Administration, zanubrutinib

Brukinsa (zanubrutinib), BeiGene, FDA approval, follicular lymphoma, accelerated approval, obinutuzumab (Gazyva) combination therapy, ROSEWOOD trial, overall response rate (ORR), disease progression or unacceptable toxicity, competition with CAR-T cell therapies/ bispecific antibodies